Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: The example of licofelone

Drugs and Aging

Volumn 22, Issue 5, 2005, Pages 394-403

  Cicero, Arrigo F G ^a   Derosa, Giuseppe ^b   Gaddi, Antonio ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c Clinical Medicine and Applied Biotechnology Department 'Campanacci'   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (7 TERT BUTYL 2,3 DIHYDRO 3,3 DIMETHYLBENZO[B]FURAN 5 YL) 4 CYCLOPROPYL 1 BUTANONE; 2 ACETYLTHIOPHENE 2 THIAZOLYLHYDRAZONE; 2,6 DI TERT BUTYL 4 [2 (5 METHYL 1H PYRAZOL 3 YL)VINYL]PHENOL; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 4 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 2 METHYL 1,2 OXAZIN 3 ONE; 6,7 DIHYDRO 2 [4 (METHYLSULFINYL)PHENYL] 3 (4 PYRIDYL) 5H PYRROLO[1,2 A]IMIDAZOLE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CI 986; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FPL 62064; L 652343; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PD 137968; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB; ACETIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DUODENUM ULCER; ELDERLY CARE; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; LEG EDEMA; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SODIUM ABSORPTION; STOMACH INJURY; STOMACH ULCER; AGED; ANIMAL;

ACETIC ACIDS; AGED; ANIMALS; CLINICAL TRIALS; COMORBIDITY; CYCLOOXYGENASE INHIBITORS; HUMANS; LIPOXYGENASE INHIBITORS; PYRROLES;

EID: 22344444226     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Patel P, Zed PJ. Drug-related visits to the emergency department: how big is the problem? Pharmacotherapy 2002; 22 (7): 915-23
2. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287 (3): 337-44
3. Hochberg MC, Dougados M. Pharmacological therapy of osteo-arthritis. Best Pract Res Clin Rheumatol 2001; 15 (4): 583-93
4. Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002; 11 (4): 430-43
5. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002; 9: 1033-43
6. Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29 (3): 467-73
7. Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003; 62 (5): 501-9
8. Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Arch Immunol Ther Exp 2001; 49 (3): 177-88
9. Fiorucci S, Meli R, Bucci M, et al. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: a new avenue in anti-inflammatory therapy? Biochem Pharmacol 2001; 62 (11): 1433-8
10. Pope JE, Anderson JJ, Felson DT. A meta analysis of the effect of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477-84
11. Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community based cross sectional study. Br J Clin Pharmacol 1993; 35: 455-9
12. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease (Pt 2): short-term reductions in blood pressure - overview of randomised drug trials in their epidemiological context. Lancet 1990; 335 (8693): 827-38
13. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow up of prospective studies. Am J Epidemiol 1999; 150 (4): 341-53
14. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11 (4): 382-7
15. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068-73
16. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104 (19): 2280-8
17. J̈uni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021-9
18. Okie S. Raising the safety bar: the FDA's coxib meeting. N Engl J Med 2005; 352: 1283-5
19. Bykerk VP, Keystone EC. What are the goals and principles of management in the early treatment of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2005; 19: 147-61
20. Andrieu S, Lebret M, Maclouf J, et al. Effects of antiaggregant and anti-inflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs. J Cardiovasc Pharmacol 1999; 33 (2): 264-72
21. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1977. Arthritis, Rheumatism, and Aging Medical Information System. J Rheu-matol 1998; 51 Suppl.: 8-16
22. Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38 (6): 666-71
23. Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001; 23 (9): 1323-38
24. Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160 (19): 2998-3003
25. Halter F, Tarnawski AS, Schmassmann A, et al. Cyclooxygenase 2: implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49 (3): 443-53
26. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343: 1520-8
27. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55
28. Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222-4
29. DeMaria AN. NSAIDs, COXIBs and cardio-renal physiology. In: Health Science Center for Continuing Medical Education, editor. San Diego (CA), 2000: Health Science Center for Continuing Medical Education, 1-37
30. Welthon A. Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63-74
31. Harris CJ, Brater DC. Renal effects of cyclooxygenase-2 selective inhibitors. Curr Opin Nephrol Hypertens 2001; 10 (5): 603-10
32. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133 (1): 1-9
33. Appel GB. COX-2 inhibitors and the kidney. Clin Exp Rheumatol 2001; 19 (S): 37-40
34. Ailabouni W, Eknoyan G. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly: a risk-benefit assessment. Drugs Aging 1996; 9 (5): 341-51
35. Clarkson MR, McGinthy A, Godson C, et al. Leucotryenes and lipoxins: lipooxygenase-derived modulators of leukocyte recruitment and vascular tone in glomeruloneprhitis. Nephrol Dial Transplant 1998; 13: 3043-51
36. Deray G. Renal tolerance to selective inhibitors of cyclooxygenase type 2. Presse Med 2001; 30: 1507-12
37. Whelton A, Braler DC, Sica DA. Effects of cycloxygenase-2 inhibition on renal function in the elderly [abstract]. J Am Soc Nephr 1999; 10: 92A
38. Hanlon JT, Schmader KE, Koronoswki MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945-8
39. Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J Rheumatol 2001; 28 (11): 2375-82
40. Dahlén S-E. 5-Lipoxygenase inhibitors. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Progress in Respiratory Research. Vol. 31. Basel: Karger, 2001: 115-20
41. Petty TL. COPD in perspective. Chest 2002; 121 (5 Suppl.): 116S-20S
42. Gaddi A, Cicero AFG, Pedro E. Clinical perspectives of anti-inflammatory therapy in the elderly: the lypoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr 2004; 38 (3): 201-12
43. Lajeunesse D, Paredes Y, Massicotte F, et al. Role of leukotriene B4 in the abnormal function of human subcondral osteoarthritic osteoblasts: effect of the combined inhibition of cyclooxygenase and 5-lipoxygenase (5-LOX) by licofelone (ML3000). In: EULAR 2002, Annual European Congress of Rheumatology; 2002 June 12-15; Stockholm, Sweden. Ann Rheum Dis 2002; 61 (S1): 175
44. Leval X, Julemont F, Delarge J, et al. New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9 (9): 941-62
45. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem: the dual inhibition concept. Pharmacol Res 2001; 43 (5): 429-36
46. Rabasseda X, Mealy N, Castaner J. ML-3000. Drugs Future 1995; 20: 1007-9
47. Laufer S, Tries S, Augustin J, et al. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase. Arzneimittelforschung 1994; 44: 629-36
48. Abraham WM, Laufer S, Tries S. The effects of ML 3000 on antigen-induced responses in sheep. Pulm Pharmacol Ther 1997; 10: 167-73
49. Laufer S, Tries S, Augustin J, et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H- pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung 1995; 45: 27-32
50. Rotondo S, Krauze Brzosko K, et al. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1- dependent platelet activation. Eur J Pharmacol 2004; 488 (1-3): 79-83
51. Rotondo S, Dell'Elba G, Krauze Brzosko K, et al. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet. Eur J Pharmacol 2002; 453 (1): 131-9
52. Algate DR, Augustin J, Atterson PR, et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl] -acetic acid in experimental animals. Arzneimittelforschung 1995; 45: 159-16
53. Heidemann A, Tries S, Laufer S, et al. Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H- pyrrolizine-5-yl]-acetic acid. Arzneimittel Forschung 1995; 45: 486-90
54. Wallace JL, Carter L, McKnight W, et al. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 1994; 271: 525-31
55. Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002; 51 (3): 135-43
56. Fiorucci S, Distrutti E, De Lima OM, et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17 (9): 1171-3
57. Buchner A, Bias P, Lammerich A. Twice the therapeutic dose of licofelone - an inhibitor of COX-1, COX-2 and 5-LOX - results in a significantly lower gastrointestinal ulcer incidence than naproxen in osteoarthritis patients, when administered with or without concomitant low-dose aspirin [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 261
58. Gay RE, Neidhart M, Pataky F, et al. Dual inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J Rheumatol 2001; 28: 2060-5
59. Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Arthritis Rheum 2001; 44: 2320-30
60. Pelletier J-P, Di Battista JA, Raynoud JP, et al. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1 and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995; 72: 578-86
61. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response. J Immunol 1992; 148: 480-4
62. Pelletier J-P, Lajennesse D, Jovanovic DV, et al. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol 2000; 27: 2893-902
63. Pelletier J-P, Martel-Pelletier J. In vivo protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog model. J Rheumatol Suppl 1991; 27: 127-30
64. Palmoski MJ, Brandt KD. In vivo effect of aspirin on canine osteoarthritic cartilage. Arthritis Rheum 1983; 26: 994-1001
65. Paredes Y, Massicotte F, Pelletier J-P, et al. Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 2002; 46 (7): 1804-12
66. Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture; comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol 1996; 48: 46-52
67. Bias P, Buchner A, Klesser B, et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volun teers: results from a randomized, controlled trial. Am J Gastroenterol 2004; 99 (4): 611-8
68. Reginster JY, Bias P, Buchner A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthtritis. Ann Rheum Dis 2002; 61 (1 Suppl.): 116
69. Bias P, Buchner A, Lammerich A. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, has an excellent tolerability profile when given in single doses of up to 16-fold the therapeutic dose [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 479
70. Blanco FJ, Buchner A, Bias P, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 261
71. Pavelka K, Bias P, Buchner A, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the knee [abstract]. Ann Rheum Dis 2003; 62 Suppl. 1: 261